



## Filing of 10Q form

November 7, 2024 7:00 AM EST

RNS Number : 2437L

MaxCyte, Inc.

07 November 2024

### **MaxCyte announces filing of Form 10-Q for the quarterly period ended September 30, 2024**

**ROCKVILLE, MD, November 7, 2024** - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has filed a Form 10-Q with the SEC for the quarterly period ended September 30, 2024.

A copy of the Form 10-Q is available to view on the SEC's website at [www.sec.gov](http://www.sec.gov) and has also been posted to the "SEC filings" page of the Company's website, <https://investors.maxcyte.com/>

#### **About MaxCyte**

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our EXPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The EXPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](http://maxcyte.com) and follow us on X and LinkedIn.

#### **MaxCyte Contacts:**

##### **US IR Adviser**

##### **Gilmartin Group**

David Deuchler, CFA

+1 415-937-5400

[ir@maxcyte.com](mailto:ir@maxcyte.com)

##### **Nominated Adviser and Joint Corporate Broker**

##### **Panmure Liberum**

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

**UK IR Adviser**

**ICR Healthcare**

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

[maxcyte@icrhealthcare.com](mailto:maxcyte@icrhealthcare.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DOCQKABNOBDDFDK